REG - ValiRx PLC - Conclusion of Evaluation Project

ValiRxAnnouncement

26/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ6800Fa&default-theme=true

RNS Number : 6800F  ValiRx PLC  26 September 2024

26 September 2024

 

ValiRx PLC ("ValiRx" or the "Company")

 

Conclusion of Evaluation Project

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update at the conclusion of the Evaluation project from the University of
Barcelona announced on 7 June 2023.

On entering the broader collaboration agreement with Barcelona University in
June 2023, the Company tested drug candidates from the series "KRAS2" in a
barrage of in silico and in vitro tests.  After expanding the series of
molecules through in silico study, a selection of candidates were synthesised
and tested for anti-cancer activity as a monotherapy and in combination with
standard chemotherapy agents within the laboratory at Inaphaea BioLabs
Limited.

Although initial results show promise, the development programme is at an
early stage, and the Company has decided to return the project to the
university researchers for further development, with no further financial
commitment from the Company. The parties have agreed to terminate the current
collaboration agreement and revert responsibility for maintaining the
intellectual property to Barcelona University.

Mark Eccleston, CEO of ValiRx commented "Working alongside the University of
Barcelona team on this project has been an engaging experience, and although
we are not in a position to progress with this lead series of molecules at
this stage, we look forward to retaining close contact with the team at
Barcelona to hear further updates on these and other projects which could lead
to future agreements."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

*** ENDS ***

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            M (mailto:Suzanne.Dilly@valirx.com) ark.eccleston@valirx.com

                                                 (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKPBQPBKDQCB